AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7% – Should You Sell?

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price fell 5.7% on Tuesday . The stock traded as low as $19.80 and last traded at $20.02. 174,378 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,165,128 shares. The stock had previously closed at $21.22.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating and issued a $19.00 price target on shares of AnaptysBio in a research note on Tuesday, February 4th. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. dropped their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wolfe Research began coverage on AnaptysBio in a report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Truist Financial cut their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.45.

AnaptysBio Stock Down 3.8 %

The company has a fifty day moving average price of $15.81 and a two-hundred day moving average price of $25.36. The firm has a market capitalization of $574.21 million and a price-to-earnings ratio of -3.10.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc acquired 6,646 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the transaction, the director now owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 33.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently modified their holdings of ANAB. Tower Research Capital LLC TRC raised its position in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in AnaptysBio during the fourth quarter worth about $40,000. Values First Advisors Inc. acquired a new stake in AnaptysBio in the third quarter valued at about $49,000. AlphaQuest LLC increased its position in AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 4,237 shares during the period. Finally, Virtus ETF Advisers LLC raised its stake in shares of AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after buying an additional 936 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.